Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Precision BioSciences, Inc. before investing.

In this article, we go over a few key elements for understanding Precision BioSciences, Inc.’s stock price such as:

• Precision BioSciences, Inc.’s current stock price and volume
• Why Precision BioSciences, Inc.’s stock price changed recently
• Upgrades and downgrades for DTIL from analysts
• DTIL’s stock price momentum as measured by its relative strength

About Precision BioSciences, Inc. (DTIL)

Before we jump into Precision BioSciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Want to learn more about Precision BioSciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Precision BioSciences, Inc..

Precision BioSciences, Inc.’s Stock Price as of Market Close

As of December 10, 2025, 10:02 AM, CST, Precision BioSciences, Inc.’s stock price was $4.840.

Precision BioSciences, Inc. is down 0.41% from its previous closing price of $4.860.

During the last market session, Precision BioSciences, Inc.’s stock traded between $4.839 and $4.930. Currently, there are approximately 11.82 million shares outstanding for Precision BioSciences, Inc..

Precision BioSciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Precision BioSciences, Inc. Stock Price History

Precision BioSciences, Inc.’s (DTIL) price is currently down 11.03% so far this month.

During the month of December, Precision BioSciences, Inc.’s stock price has reached a high of $5.540 and a low of $4.610.

Over the last year, Precision BioSciences, Inc. has hit prices as high as $8.820 and as low as $3.610. Year to date, Precision BioSciences, Inc.’s stock is up 27.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Precision BioSciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of December 09, 2025,, no analysts have changed their rating of Precision BioSciences, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Precision BioSciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Precision BioSciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Precision BioSciences, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Precision BioSciences, Inc. (DTIL) by visiting AAII Stock Evaluator.

Relative Price Strength of Precision BioSciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 09, 2025, Precision BioSciences, Inc. has a weighted four-quarter relative price strength of -8.80%, which translates to a Momentum Score of 27 and is considered to be Weak.

Want to learn more about how Precision BioSciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Precision BioSciences, Inc. Stock Price: Bottom Line

As of December 10, 2025, Precision BioSciences, Inc.’s stock price is $4.840, which is down 0.41% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Precision BioSciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.